Pajvani U - Search Results

1

The relationship between family medical history and childhood vitiligo.

Pajvani U, Ahmad N, Wiley A, Levy RM, Kundu R, Mancini AJ, Chamlin S, Wagner A, Paller AS. Pajvani U, et al. J Am Acad Dermatol. 2006 Aug;55(2):238-44. doi: 10.1016/j.jaad.2006.02.027. Epub 2006 May 18. J Am Acad Dermatol. 2006. PMID: 16844505

2

Safety of radiofrequency treatment over human skin previously injected with medium-term injectable soft-tissue augmentation materials: a controlled pilot trial.

Alam M, Levy R, Pajvani U, Ramierez JA, Guitart J, Veen H, Gladstone HB. Alam M, et al. Among authors: pajvani u. Lasers Surg Med. 2006 Mar;38(3):205-10. doi: 10.1002/lsm.20241. Lasers Surg Med. 2006. PMID: 16532442 Clinical Trial.

3

Kisspeptin Alleviates Human Hepatic Fibrogenesis by Inhibiting TGFβ Signaling in Hepatic Stellate Cells.

Prasad K, Bhattacharya D, Shams SGE, Izarraras K, Hart T, Mayfield B, Blaszczyk MB, Zhou Z, Pajvani UB, Friedman SL, Bhattacharya M. Prasad K, et al. Among authors: pajvani ub. Cells. 2024 Oct 4;13(19):1651. doi: 10.3390/cells13191651. Cells. 2024. PMID: 39404414 Free PMC article.

4

KCTD17-mediated Ras stabilization promotes hepatocellular carcinoma progression.

Jung YH, Lee YJ, Dao T, Jung KH, Yu J, Oh AR, Jeong Y, Gi H, Kim YU, Ryu D, Carrer M, Pajvani UB, Lee SB, Hong SS, Kim K. Jung YH, et al. Among authors: pajvani ub. Clin Mol Hepatol. 2024 Oct;30(4):895-913. doi: 10.3350/cmh.2024.0364. Epub 2024 Aug 5. Clin Mol Hepatol. 2024. PMID: 39098817 Free PMC article.

5

Diabetes mellitus-Progress and opportunities in the evolving epidemic.

Abel ED, Gloyn AL, Evans-Molina C, Joseph JJ, Misra S, Pajvani UB, Simcox J, Susztak K, Drucker DJ. Abel ED, et al. Among authors: pajvani ub. Cell. 2024 Jul 25;187(15):3789-3820. doi: 10.1016/j.cell.2024.06.029. Cell. 2024. PMID: 39059357 Review.

6

Calorie restriction activates a gastric Notch-FOXO1 pathway to expand ghrelin cells.

McKimpson WM, Spiegel S, Mukhanova M, Kraakman M, Du W, Kitamoto T, Yu J, Deng Z, Pajvani U, Accili D. McKimpson WM, et al. Among authors: pajvani u. J Cell Biol. 2024 Oct 7;223(10):e202305093. doi: 10.1083/jcb.202305093. Epub 2024 Jul 3. J Cell Biol. 2024. PMID: 38958606

7

The first MASH drug therapy on the horizon: Current perspectives of resmetirom.

Petta S, Targher G, Romeo S, Pajvani UB, Zheng MH, Aghemo A, Valenti LVC. Petta S, et al. Among authors: pajvani ub. Liver Int. 2024 Jul;44(7):1526-1536. doi: 10.1111/liv.15930. Epub 2024 Apr 5. Liver Int. 2024. PMID: 38578141 Free article. Review.

8

Protective hepatocyte signals restrain liver fibrosis in metabolic dysfunction-associated steatohepatitis.

Steffani M, Geng Y, Pajvani UB, Schwabe RF. Steffani M, et al. Among authors: pajvani ub. J Clin Invest. 2024 Apr 1;134(7):e179710. doi: 10.1172/JCI179710. J Clin Invest. 2024. PMID: 38557494 Free PMC article.

9

β-cell Jagged1 is sufficient but not necessary for islet Notch activity and insulin secretory defects in obese mice.

Suda N, Bartolomé A, Liang J, Son J, Yagishita Y, Siebel C, Accili D, Ding H, Pajvani UB. Suda N, et al. Among authors: pajvani ub. Mol Metab. 2024 Mar;81:101894. doi: 10.1016/j.molmet.2024.101894. Epub 2024 Feb 3. Mol Metab. 2024. PMID: 38311286 Free PMC article.

10

Author Correction: Inhibition of Notch signaling ameliorates insulin resistance in a FoxO1-dependent manner.

Pajvani UB, Shawber CJ, Samuel VT, Birkenfeld AL, Shulman GI, Kitajewski J, Accili D. Pajvani UB, et al. Nat Med. 2024 Feb;30(2):604. doi: 10.1038/s41591-023-02695-9. Nat Med. 2024. PMID: 38041001 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

85 results

Search Page

Filters